AACR Annual Meeting 2024, San Diego, CA, April 5-10
Conference
genOway presentation
genOway’s program at AACR 2024
Spotlight Theater workshop
Title: "Presence of myeloid and lymphoid cells are key for translational tumor biology, efficacy and safety assessment in humanized mouse models"
Summary:
- The presence of human myeloid and lymphoid compartments in preclinical humanized models contributes to their relevancy and translatability. As new therapeutic approaches co-target both compartments, this has become a key feature of drug development which is both critical and challenging, due to most mouse models exhibiting a short life-span and severe side effects when the myeloid compartment is induced.
- Our BRGSF-HIS model is an immunodeficient mouse which exhibits both functional human lymphoid and myeloid compartments.
- Human immune cell recruitment and activation into the TME is tumor-dependent, evidencing the functionality of the immune response in the BRGSF-HIS model.
- The assessment of TCE’s safety in the BRGSF-HIS model revealed that myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome (CRS) features in the model.
- The BRGSF-HIS model enables therapeutics’ MoA investigation.
Our posters
Below are the four posters presented by our team at the conference:
#5292
Title: "CD28 humanized mouse model for efficacy and safety assessment of CD28-targeting therapies" — Our humanized CD28 mouse model allows for the assessment of CD28-targeting agents' efficacy and safety, facilitating studies on combination therapies and bispecific antibodies targeting CD3 and CD28.
#1530
Title: "Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in BRGSF-HIS mice" — Our highly immunodeficient mouse model reconstituted with human cord blood CD34+ cells, BRGSF-HIS, provides a stable and permissive environment for studying cancer development and testing novel therapeutics, with response to treatment reflecting clinical heterogeneity and enabling further investigation of treatment mechanisms and immune escape.
#2045
Title: "Novel TFRC humanized mouse model for drug delivery to the brain" — hTFRC was developed to assess compounds targeting human TFRC for delivery through the blood-brainbarrier (BBB) and the efficient shuttling of therapeutic antibodies to the brain.
#5341
Title: "Novel FcγR humanized mouse models enable assessment of PK/PD of therapeutic antibodies" — We developed a mouse model expressing humanized Fcγ receptors with a human-like expression pattern, enabling assessment of therapeutic antibodies' enhanced activity and functionality, with potential applications in evaluating Fc-engineered therapeutic antibodies and improving translatability in pharmacokinetic assessments.
Our clients' posters
Below are posters presented by clients using our models:
- MACOMICS │ "Discovery of MACO355: a first in mechanism ligand-blocking independent LILRB1/2/3 antibody for cancer therapy" — Model used: BRGSF-HIS mouse
- Cidara Therapeutics │ "Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model — Models used: PD-1/PD-L1 mouse and M38 hPD-L1-LZ cell line
AACR Annual Meeting 2024, San Diego, CA, April 5-10
Get in touch about
Let us know how we can help